Benzinga | Nov 2, 2021 05:45PM EDT

Aquestive Therapeutics Sees FY21 Revs $47M-$49M Vs $48.32M Est

2021 Outlook

Sympazan and the Company's other on-going business activities generated strong operating results during the first half of 2021. As a result, the Company has revised its full year expectations as follows:

Updated Guidance Prior GuidanceTotal revenue (in millions) $47 to $49 $46 to $48Non-GAAP adjusted gross margins 70% to 75% 70% to 75%Non-GAAP adjusted EBITDA loss (in millions) $32 to $34 $39 to $42